The Metabolic Syndrome Is an Important Concept in Therapeutic Decision-Making

Canadian Journal of Cardiology

Volumn 31, Issue 5, 2015, Pages 596-600

  Fitchett, David ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ANTERIOR MYOCARDIAL INFARCTION; ARTICLE; BLOOD PRESSURE; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CASE REPORT; CORONARY ARTERY ATHEROSCLEROSIS; DYSGLYCEMIA; DYSLIPIDEMIA; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WORLD HEALTH ORGANIZATION; AGE DISTRIBUTION; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMORBIDITY; DECISION MAKING; EARLY DIAGNOSIS; FEMALE; INCIDENCE; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SEX RATIO; SURVIVAL RATE;

AGE DISTRIBUTION; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; COMORBIDITY; DECISION MAKING; EARLY DIAGNOSIS; FEMALE; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 84928824874     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.10.037     Document Type: Article

References (25)

1. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart study. Circulation 2008, 117:743-753.
2. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): case-control study. Lancet 2004, 364:937-952.
3. Mente A., Yusuf S., Islam S., et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. JAm Coll Cardiol 2010, 55:2390-2398.
4. Cardiometabolic Risk Working Group, Leiter L.A., Fitchett D.H., et al. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol 2011, 27:e1-33.
5. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
6. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004, 24:e13-e18.
7. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
8. Lemieux I., Poirier P., Bergeron J., et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?. Can J Cardiol 2007, 23(suppl B):23B-31B.
9. Despres J.P., Lemieux I., Bergeron J., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
10. Lamarche B., Tchernof A., Mauriege P., et al. Fasting insulin and apolipoprotein b levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279:1955-1961.
11. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among us adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
12. Beltran-Sanchez H., Harhay M.O., Harhay M.M., McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. JAm Coll Cardiol 2013, 62:697-703.
13. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119:812-819.
14. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. JAm Coll Cardiol 2007, 49:403-414.
15. Daly C.A., Hildebrandt P., Bertrand M., et al. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007, 93:1406-1411.
16. de Simone G., Devereux R.B., Chinali M., et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 2007, 30:1851-1856.
17. Noto D., Barbagallo C.M., Cefalu A.B., et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008, 197:147-153.
18. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
19. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
20. Fitchett D.H., Mancini G.B., Gregoire J., Anderson T., McPherson R. Risk stratification and selection for statin therapy: going beyond Framingham. Can J Cardiol 2014, 30:667-670.
21. Hirsso P.K., Timonen M.J., Jokelainen J.J., et al. Association between high-sensitive measurement of c-reactive protein and metabolic syndrome as defined by International Diabetes Federation, National Cholesterol Education Program, and World Health Organization criteria in a population-based cohort of 55-year-old Finnish individuals. Diabetes Care 2006, 29:2177-2178.
22. Devaraj S., Singh U., Jialal I. Human c-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009, 20:182-189.
23. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
24. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. NEngl J Med 2008, 359:2195-2207.
25. Teoh H., Despres J.P., Dufour R., et al. Identification and management of patients at elevated cardiometabolic risk in Canadian primary care: how well are we doing?. Can J Cardiol 2013, 29:960-968.